Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 226

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 226
---
:----|-----------:|:--|
| Non-capital losses carry forward - Canada |     |               1,973,535 |   |     |    561,698 |   |
| Net operating losses carry forward - US   |     |               2,678,919 |   |     |  2,208,235 |   |
| Intangible assets                         |     |                  10,855 |   |     |     11,810 |   |
| Accrued expenses                          |     |                 994,653 |   |     |    170,598 |   |
| Research and Development Tax credits      |     |                 242,190 |   |     |    242,190 |   |
| Other                                     |     |                  14,230 |   |     |     25,290 |   |
| Financing charges and interest            |     |                 668,701 |   |     |          - |   |
| Total deferred tax assets                 |     |               6,583,083 |   |     |  3,219,821 |   |
| Less: valuation allowance                 |     |              (6,583,083 | ) |     | (3,219,821 | ) |
| Deferred tax assets, net                  |     |                       - |   |     |          - |   |

The Company has a valuation allowance on all of its deferred tax assets at December 31, 2024 and 2023, which based in the judgement of management are not more-likely than-not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that all or some portion of the deferred assets will not be realized. This ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those deductible temporary difference become deductible. Based on the history of losses and projections for future taxable income, management believes that it is not more-likely than-not that the Company will realize the benefits of these deductible temporary differences (e.g. deferred tax assets). The Company has $242,190 of US Research and Development Tax Credits which are available to reduce future US taxes payable and begin to expire in 2036. In addition, the Company has gross Canadian non-capital loss carryforwards of $7,447,301. To the extent that the non-capital loss carryforwards are not used, they begin to expire in 202